A randomised, double-blind, study comparing ARIMIDEX with NOLVADEX as neo-adjuvant and adjuvant treatment in post-menopausal women with large operable (T2 [at least 3cm], T3, N0-2, M0) or potentially operable, locally advanced (T4b, N0-2, M0), ER+ and/or PR+ breast cancer.

Trial Profile

A randomised, double-blind, study comparing ARIMIDEX with NOLVADEX as neo-adjuvant and adjuvant treatment in post-menopausal women with large operable (T2 [at least 3cm], T3, N0-2, M0) or potentially operable, locally advanced (T4b, N0-2, M0), ER+ and/or PR+ breast cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Anastrozole (Primary) ; Tamoxifen
  • Indications Advanced breast cancer; Menopause
  • Focus Therapeutic Use
  • Acronyms PROACT
  • Most Recent Events

    • 12 May 2009 Patient numbers amended from 451 to 452 as reported by ClinicalTrials.gov.
    • 05 Feb 2008 Status changed from in progress to completed; according to clinicaltrials.gov.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top